Key Highlights

  • Third-quarter Revenue was USD 19 million, down 8% from a year earlier, as a USD 2 million decline in OviTex PRS outweighed growth in international sales, management said on the November 10, 2026 call.
  • Adjusted EBITDA loss narrowed to USD 3.4 million, an improvement of 40% year over year and 56% sequentially, after a realignment that management said will save USD 17 million annually.
  • Gross Margin was 64.9% against 67.5% a year ago, and management said it would have been 71% without a USD 1.1 million noncash excess and obsolete inventory charge.
  • Cash and cash equivalents were USD 22.7 million at September 30, 2026, versus USD 50.8 million at December 31, 2025, and the 10-Q cites substantial doubt about continuing as a going concern.

Revenue Slips 8% as OviTex PRS Drags on the Quarter

TELA Bio (NASDAQ:TELA) filed its 10-Q for the quarter ended September 30, 2026 on November 10, 2026, the same day as its earnings call. The commercial-stage medical technology company sells OviTex reinforced tissue matrices for hernia repair and plastic and reconstructive surgery. Revenue was USD 19 million, down 8%, with the U.S. contributing USD 15.4 million and Europe USD 3.6 million. OviTex PRS revenue fell 20% year over year and 6% sequentially, a decline management said was concentrated in a limited number of markets after surgeon departures and sales turnover. Europe grew 18%, driven by higher-value complex cases, particularly in the U.K. U.S. hernia revenue was down slightly year over year, though Volume grew and LIQUIFIX set a quarterly sales record.

A USD 17 Million Savings Plan Narrows the Loss

Total operating expenses excluding other expenses fell 17.8% to USD 17.6 million from USD 21.4 million, and loss from operations was USD 7.3 million, a USD 0.3 million improvement. Management attributed the gains to a September realignment that included a headcount reduction of about 20%. Gross Profit was USD 12.3 million compared with USD 14.0 million a year earlier. For the nine months, the 10-Q shows a net loss of USD 32.8 million versus USD 29.8 million, and Operating Activities used USD 29.2 million of cash. The company received 510(k) clearance in September 2026 for Liora, a resorbable mesh developed in its own cleanroom.

Going Concern Doubt, Covenant Relief and Nasdaq Compliance

The 10-Q says forecasts make it probable that TELA Bio (NASDAQ:TELA) will miss the minimum revenue threshold in its Perceptive Credit agreement over the next twelve months, which raises substantial doubt about its ability to continue as a going concern. Perceptive agreed to suspend minimum revenue covenant testing for the quarters ending September 30 and December 31, 2026, which management described as specific to that covenant. Negative Working Capital of USD 28.3 million reflects the reclassification of debt. Separately, Nasdaq confirmed on October 5 that the company regained compliance with its minimum bid price rule, and management said it does not plan a Reverse Stock Split now, though it keeps the option for 12 months.

Where Things Stand

The loss narrowed because costs fell faster than sales. TELA Bio (NASDAQ:TELA) cut operating expenses by 17.8% and trimmed its adjusted EBITDA loss by 40% to USD 3.4 million, even as revenue dropped 8% to USD 19 million on weaker OviTex PRS demand. The Balance Sheet is the open question: cash was USD 22.7 million, the filing flags Going Concern doubt, and covenant testing is paused only for two quarters. On the call, management said it expects sequential improvement in the fourth quarter and will update the Liora commercial plan in early 2027, but gave no numeric guidance.